|
|
|||
| |||||||||||||||||||||||||||||||||||||||
Because of the rising number of such high-priced medications, some insurers have begun to revise their tiered drug-copayment structures, which have generally delineated
Source Information
Dr. Lee is network president at Partners Healthcare System, Boston, and an associate editor of the Journal. Dr. Emanuel is the chair of the Department of Bioethics, National Institutes of Health, Bethesda, MD.
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | TERMS OF USE | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved. |